Oncology Central

Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2- metastatic breast cancer

0

Breast cancer (BC) rates are among the highest in cancer incidence and mortality. Most commonly, these patients are erb2 negative and hormone receptor (HR)-positive and thus, receive hormonal therapy as a cornerstone of their treatment in the advanced setting [1]. The majority of these patients respond to hormonal therapy but primary or secondary resistances may be observed. Several resistance mechanisms have been shown to drive the tumor proliferation, growth, cell cycle and progression via upregulation of alternate signaling including EGFR, PI3K, mTOR and CDK4/6 pathways [2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.